MBRX 8-K SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

MBRX ▼ -10.68% at T+5d

NEUTRAL call ✗ call lost -10.68% · α vs SPY -10.76% · entry $2.34 → $2.09

Next anchor: T+20d in 6h

Last close $2.47 (close Jun 8) · +5.56% from $2.34 entry

Entry anchored
May 11, 03:58 PM ET
via Databento tick

T+1d

-8.55%

call -8.55% · α -9.12%

$2.14

settled 28d ago

T+5d

-10.68%

call -10.68% · α -10.76%

$2.09

settled 22d ago

T+20d

—

call — · α —

—

in 6h

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Moleculin Biotech announced publication of an abstract at the EHA 2026 Congress showing no clinically significant cardiotoxicity with Annamycin in a pooled analysis of 90 R/R AML patients. The data, from an independent Cleveland Clinic review, supports the drug's cardiac safety profile but does not alter the company's financial outlook or near-term regulatory path.

Actionable Insight

The cardiac safety data is positive but expected given prior disclosures; no immediate catalyst. Monitor upcoming Phase 3 MIRACLE trial results and any regulatory interactions for meaningful stock-moving events.

Key Facts

Abstract accepted at EHA 2026 Congress highlighting cardiac safety of Annamycin.
Independent review by Cleveland Clinic of 90 patients across 5 trials showed stable ejection fraction and no clinically significant left ventricular dysfunction.
No financial guidance or material financial data provided in the filing.

Financial Impact

No financial impact reported in filing.

Risk Factors

Phase 3 trial failure could materially impair stock value.
Company requires additional financing to continue operations; no committed funding in place.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

89% bullish (9 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001437749-26-016260
Exhibit: ex_960914.htm	0001437749-26-016260
Document: 0001437749-26-016260-index-headers.html	0001437749-26-016260
Document: 0001437749-26-016260-index.html	0001437749-26-016260
Document: 0001437749-26-016260.txt	0001437749-26-016260

13 reports for MBRX

T+1T+5T+20T+60

50% Hit rate 3 of 6 directional calls best @ T+5▲ +9.81%May 13, 2026

Filters

Reports for MBRX — sortable, filterable
	Type				Now
Jun 5, 2026 4d ago	8-K BULLISH ★ 5/10	$2.58 awaiting T+5	awaiting T+5	—	$2.47 (−4.26%)
May 29, 2026 11d ago	8-K BULLISH ★ 6/10	$2.79 $2.46	▼ −11.83%	▼ −11.54%	$2.47 (−11.47%)
May 26, 2026 14d ago	8-K NEUTRAL ★ 3/10	$2.45 $2.64	▲ +7.76%	▲ +6.67%	$2.47 (+0.82%)
May 22, 2026 18d ago	8-K NEUTRAL ★ 4/10	$2.45 $2.64	▲ +7.76%	▲ +6.67%	$2.47 (+0.82%)
May 15, 2026 25d ago	8-K MIXED ★ 6/10	$2.11 $2.39	▲ +13.27%	▲ +12.31%	$2.47 (+17.06%)
May 15, 2026 25d ago	Press Release BEARISH ★ 6/10	$2.11 $2.39	▼ −13.27%	▼ −12.31%	$2.47 (−17.06%)
May 13, 2026 27d ago	8-K BULLISH ★ 6/10	$2.14 $2.35	▲ +9.81%	▲ +10.97%	$2.47 (+15.42%)
May 12, 2026 28d ago	8-K NEUTRAL ★ 3/10	$2.34 $2.09	▼ −10.68%	▼ −10.76%	$2.47 (+5.56%)
May 8, 2026 4w ago	8-K NEUTRAL ★ 3/10	$2.47 $2.20	▼ −10.93%	▼ −12.39%	$2.47 (+0.00%)
Apr 23, 2026 6w ago	8-K BULLISH ★ 6/10	$2.54 $2.51	▼ −1.18%	▼ −2.66%	$2.47 (−2.76%)

US Market Status

Market Closed — Opens in 7h 16m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access